Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Non-Current Liabilities (2021 - 2026)

Barinthus Biotherapeutics filings provide 6 years of Total Non-Current Liabilities readings, the most recent being $22.7 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities fell 9.17% to $22.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $22.7 million, a 9.17% decrease, with the full-year FY2025 number at $22.4 million, down 18.67% from a year prior.
  • Total Non-Current Liabilities hit $22.7 million in Q1 2026 for Barinthus Biotherapeutics, up from $22.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $32.6 million in Q3 2023 to a low of $22.4 million in Q4 2025.
  • Median Total Non-Current Liabilities over the past 5 years was $26.5 million (2023), compared with a mean of $26.9 million.
  • Biggest five-year swings in Total Non-Current Liabilities: grew 6.38% in 2023 and later decreased 18.67% in 2025.
  • Barinthus Biotherapeutics' Total Non-Current Liabilities stood at $26.0 million in 2022, then increased by 0.56% to $26.2 million in 2023, then grew by 5.18% to $27.5 million in 2024, then decreased by 18.67% to $22.4 million in 2025, then rose by 1.37% to $22.7 million in 2026.
  • The last three reported values for Total Non-Current Liabilities were $22.7 million (Q1 2026), $22.4 million (Q4 2025), and $23.2 million (Q3 2025) per Business Quant data.